| ²é¿´: 383 | »Ø¸´: 1 | ||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | ||
yin198716гæ (ÕýʽдÊÖ)
|
[ÇóÖú]
ÇóÖú·Òë
|
|
| Clinical resistance to anti-VEGF therapy highlights the need for targeting additional tumor angiogenesis signaling pathways. |
» ²ÂÄãϲ»¶
322Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
295·ÖÇóµ÷¼Á
ÒѾÓÐ3È˻ظ´
294Çóµ÷¼Á
ÒѾÓÐ7È˻ظ´
±¾ÈËÅ®º¢
ÒѾÓÐ10È˻ظ´
¶þ±½¼×ͪËáÀàÑÜÉúÎï
ÒѾÓÐ4È˻ظ´
Ò»Ö¾Ô¸Öпƴó²ÄÁÏÓ뻯¹¤£¬353·Ö»¹Óе÷¼ÁѧУÂð
ÒѾÓÐ11È˻ظ´
335Çóµ÷¼Á
ÒѾÓÐ23È˻ظ´
279Çóµ÷¼Á
ÒѾÓÐ13È˻ظ´
304Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
271Çóµ÷¼Á
ÒѾÓÐ39È˻ظ´

º£±ßµÄÌì
гæ (СÓÐÃûÆø)
- ·ÒëEPI: 6
- Ó¦Öú: 1 (Ó×¶ùÔ°)
- ½ð±Ò: 90.9
- É¢½ð: 100
- ºì»¨: 1
- Ìû×Ó: 87
- ÔÚÏß: 59.7Сʱ
- ³æºÅ: 2507861
- ×¢²á: 2013-06-14
2Â¥2013-06-24 13:23:30













»Ø¸´´ËÂ¥
20